Caribou Biosciences, Inc. (CRBU) |
|
4.96 -0.08 (-1.59%)
|
03-17 16:00 |
|
Open: |
4.98 |
Pre. Close: |
5.04 |
|
High:
|
5.05 |
Low:
|
4.83 |
|
Volume:
|
1,265,604 |
Market Cap:
|
304(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 7:44:48 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 7.2  One year: 8.17 |
| Support: |
Support1: 4.82 Support2: 4.01 |
| Resistance: |
Resistance1: 6.17 Resistance2: 7 |
| Pivot: |
5.6 |
| Moving Average: |
MA(5): 5.13 MA(20): 5.75
MA(100): 7.52 MA(250): 8.18 |
| MACD: |
MACD(12,26): -0.5 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 11.3 %D(3): 14.6 |
| RSI: |
RSI(14): 27.8 |
| 52-week: |
High: 13.18 Low: 4.82 |
| Average Vol(K): |
3-Month: 508 (K) 10-Days: 570 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRBU ] has closed above bottom band by 10.2%. Bollinger Bands are 16.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.06 - 5.09 |
5.09 - 5.12 |
|
Low:
|
4.74 - 4.79 |
4.79 - 4.82 |
|
Close:
|
4.89 - 4.96 |
4.96 - 5.01 |
|
Company Description |
|
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California. |
Headline News |
Mon, 20 Mar 2023
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER ... - The Bakersfield Californian
Sun, 19 Mar 2023
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ... - Digital Journal
Fri, 17 Mar 2023
These 4 Biotech Stocks Just Got ‘Fast Track’ Designation Greenlights - Yahoo Canada Finance
Mon, 13 Mar 2023
Oppenheimer Comments on Caribou Biosciences, Inc.'s Q1 2024 ... - MarketBeat
Thu, 09 Mar 2023
7 Top Gene-Editing Stocks to Buy - WTOP
Thu, 09 Mar 2023
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
61 (M) |
| Shares Float |
48 (M) |
|
% Held by Insiders
|
10.8 (%) |
|
% Held by Institutions
|
73 (%) |
|
Shares Short
|
4,280 (K) |
|
Shares Short P.Month
|
4,370 (K) |
Stock Financials |
|
EPS
|
-1.56 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-768.2 |
|
Return on Assets (ttm)
|
-16.3 |
|
Return on Equity (ttm)
|
-28.9 |
|
Qtrly Rev. Growth
|
44.2 |
|
Gross Profit (p.s.)
|
-1.12 |
|
Sales Per Share
|
0.22 |
|
EBITDA (p.s.)
|
-1.71 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-91 (M) |
|
Levered Free Cash Flow
|
-56 (M) |
Stock Valuations |
|
PE Ratio
|
-3.18 |
|
PEG Ratio
|
0.2 |
|
Price to Book value
|
1 |
|
Price to Sales
|
21.95 |
|
Price to Cash Flow
|
-3.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
